Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring

Hypertension

Volumn 65, Issue 1, 2015, Pages 232-237

  Wu, Zhixiong ^a   Siuda, Daniel ^a   Xia, Ning ^a   Reifenberg, Gisela ^a   Daiber, Andreas ^a   Münzel, Thomas ^a   Förstermann, Ulrich ^a   Li, Huige ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Epigenetics; Fetal Programming; Hypertension; Pentaerythritol Tetranitrate

Indexed keywords

ACETYLCHOLINE; DNA DIRECTED RNA POLYMERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE 1; HEME OXYGENASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PENTAERYTHRITYL TETRANITRATE; REACTIVE OXYGEN METABOLITE; RNA POLYMERASE II; SUPEROXIDE DISMUTASE; DNA; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTRON SPIN RESONANCE; EPIGENETICS; FEMALE; GENE EXPRESSION; HEREDITARY HYPERTENSION; LACTATION; MATERNAL TREATMENT; MEAN ARTERIAL PRESSURE; NONHUMAN; PREGNANCY; PROGENY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION INITIATION SITE; UPREGULATION; WEANING; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; BREEDING; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION REGULATION; GENETICS; HYPERTENSION; MALE; NEWBORN; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; DNA; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HYPERTENSION; MALE; MATERNAL EXPOSURE; NITRIC OXIDE SYNTHASE TYPE III; PENTAERYTHRITOL TETRANITRATE; PREGNANCY; PREGNANCY, ANIMAL; RATS; RATS, INBRED SHR; VASODILATION; VASODILATOR AGENTS;

EID: 84919418980     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04416     Document Type: Article

References (25)

1. Liang M, Cowley AW Jr, Mattson DL, Kotchen TA, Liu Y. Epigenomics of hypertension. Semin Nephrol. 2013;33:392-399.
2. Millis RM. Epigenetics and hypertension. Curr Hypertens Rep. 2011;13:21-28.
3. Lee SK, Sirajudeen KN, Sundaram A, Zakaria R, Singh HJ. Effect of cross-fostering on renal anti-oxidant/oxidant status and development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2011;38:854-859.
4. Siew-Keah L, Sundaram A, Sirajudeen KN, Zakaria R, Singh HJ. Effect of melatonin supplementation and cross-fostering on renal glutathione system and development of hypertension in spontaneously hypertensive rats. J Physiol Biochem. 2014;70:73-79.
5. Lee HA, Cho HM, Lee DY, Kim KC, Han HS, Kim IK. Tissue-specific upregulation of angiotensin-converting enzyme 1 in spontaneously hypertensive rats through histone code modifications. Hypertension. 2012;59:621-626.
6. Lee HA, Lee DY, Lee HJ, Han HS, Kim I. Enrichment of (pro)renin receptor promoter with activating histone codes in the kidneys of spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2012;13:11-18.
7. Racasan S, Braam B, van der Giezen DM, Goldschmeding R, Boer P, Koomans HA, Joles JA. Perinatal L-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension. 2004;44:83-88.
8. Racasan S, Braam B, Koomans HA, Joles JA. Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon. Am J Physiol Renal Physiol. 2005;288:F626-F636.
9. Koeners MP, van Faassen EE, Wesseling S, de Sain-van der Velden M, Koomans HA, Braam B, Joles JA. Maternal supplementation with citrulline increases renal nitric oxide in young spontaneously hypertensive rats and has long-term antihypertensive effects. Hypertension. 2007;50:1077-1084.
10. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
11. Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, Mollnau H, Stalleicken D, Weiner H, Lehmann J, Li H, Förstermann U, Münzel T, Daiber A. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol. 2007;27:1729-1735.
12. Schuhmacher S, Wenzel P, Schulz E, et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension. 2010;55:897-904.
13. Schuhmacher S, Oelze M, Bollmann F, et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes. 2011;60:2608-2616.
14. Knorr M, Hausding M, Kröller-Schuhmacher S, Steven S, Oelze M, Heeren T, Scholz A, Gori T, Wenzel P, Schulz E, Daiber A, Münzel T. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol. 2011;31:2223-2231.
15. Oppermann M, Balz V, Adams V, Dao VT, Bas M, Suvorava T, Kojda G. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med. 2009;13:1271-1278.
16. Siuda D, Zechner U, El Hajj N, Prawitt D, Langer D, Xia N, Horke S, Pautz A, Kleinert H, Förstermann U, Li H. Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Res Cardiol. 2012;107:283.
17. Li H, Witte K, August M, Brausch I, Gödtel-Armbrust U, Habermeier A, Closs EI, Oelze M, Münzel T, Förstermann U. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol. 2006;47:2536-2544.
18. Quinn MJ Jr, Crouse LC, McFarland CA, LaFiandra EM, Johnson MS. Reproductive and developmental effects and physical and chemical properties of pentaerythritol tetranitrate (PETN) in the rat. Birth Defects Res B Dev Reprod Toxicol. 2009;86:65-71.
19. Bucher JR, Huff J, Haseman JK, Eustis SL, Lilja HS, Murthy AS. No evidence of toxicity or carcinogenicity of pentaerythritol tetranitrate given in the diet to F344 rats and B6C3F1 mice for up to two years. J Appl Toxicol. 1990;10:353-357.
20. Groten T, Lehmann T, Fitzgerald J, Bruckmann A, Kahler C, Schneider U, Schleussner E. Reduction of preeclampsia related complications with the NO-donor penterythriltetranitrat (PETN) in risk pregnancies - a prospective randomized double-blind placebo pilot study. J Reproduc Immunol. 2012;94:120-120.
21. Schleussner E, Lehmann T, Kahler C, Schneider U, Schlembach D, Groten T. Impact of the nitric oxide-donor pentaerythrityl-tetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, doubleblinded trial1). J Perinat Med. 2014:1-8.
22. Kristek F, Fáberová V, Varga I. Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats. Physiol Res. 2003;52:709-717.
23. Dovinová I, Cacányiová S, Fáberová V, Kristek F. The effect of an NO donor, pentaerythrityl tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats. Gen Physiol Biophys. 2009;28:86-93.
24. Schwartz SM, Benditt EP. Aortic endothelial cell replication. I. Effects of age and hypertension in the rat. Circ Res. 1977;41:248-255.
25. Pautz A, Rauschkolb P, Schmidt N, Art J, Oelze M, Wenzel P, Förstermann U, Daiber A, Kleinert H. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics. 2009;38:176-185.